Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study

• Published in: Urology (Ridgewood, N.J.) N.J.), 2015-01, Vol.85 (1), p.92-100
• Main Authors: Daskivich, Timothy J, Fan, Kang-Hsien, Koyama, Tatsuki, Albertsen, Peter C, Goodman, Michael, Hamilton, Ann S, Hoffman, Richard M, Stanford, Janet L, Stroup, Antoinette M, Litwin, Mark S, Penson, David F
• Format: Article
• Language: English
• Subjects: Aged; Cause of Death; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatic Neoplasms - complications; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Survival Rate; Time Factors; Urology
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/j.urology.2014.07.003

Objective To provide population-based estimates of other-cause mortality by age and comorbidity in men with prostate cancer for use at the point of care in shared decision making. Materials and Methods We sampled 3183 men with nonmetastatic prostate cancer from the Prostate Cancer Outcomes Study, a US population-based prospective cohort. Survival analysis accounting for competing risks was used to provide predictions of other-cause and cancer-specific mortality by age, comorbidity, and tumor risk through 14 years of follow-up. Results Older men had a higher absolute risk of other-cause mortality associated with comorbidity. For men with comorbidity counts of 0, 1, 2, and 3+, cumulative incidence of other-cause mortality at 14 years was 9%, 18%, 30%, and 35% for those younger than 60 years; 26%, 26%, and 48%, and 52% for those aged 60-70 years; and 49%, 57%, 66%, and 74% for those older than 70 years. Prostate cancer mortality at 14 years was 5%, 8%, and 23% for men with low-, intermediate-, and high-risk disease. Competing risk pictograms for each age/comorbidity/tumor-risk pair provide visual characterization of these risks over time. Conclusion Our survival tables may be used at the point of care as part of shared decision making. Men aged >60 years with multiple comorbidities have substantial risk of other-cause mortality within 15 years of diagnosis and should consider conservative management for low-risk disease, given its low incidence of cancer-specific mortality. Men with high-risk disease, regardless of age or comorbidity, are at greater risk for cancer mortality and may still be appropriate candidates for aggressive treatment.